Diaceutics (LON:DXRX) Shares Down 3.5% – Should You Sell?

Diaceutics PLC (LON:DXRX) dropped 3.5% on Wednesday . The company traded as low as GBX 137 ($1.71) and last traded at GBX 137 ($1.71). Approximately 168,225 shares were traded during mid-day trading, an increase of 3% from the average daily volume of 163,573 shares. The stock had previously closed at GBX 142 ($1.77).

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DXRX. Canaccord Genuity Group restated a “buy” rating and issued a GBX 160 ($1.99) target price on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and set a GBX 160 ($1.99) price objective on shares of Diaceutics in a report on Tuesday, December 17th.

Diaceutics Price Performance

The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The stock has a market cap of £115.72 million, a P/E ratio of -4,566.67 and a beta of 0.58. The firm has a 50 day moving average price of GBX 129.12 and a 200 day moving average price of GBX 128.49.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.